Tandem Capital Management Corp ADV Has $5.89 Million Stock Position in Stryker Corporation $SYK

Tandem Capital Management Corp ADV lessened its stake in shares of Stryker Corporation (NYSE:SYK) by 0.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,877 shares of the medical technology company’s stock after selling 58 shares during the quarter. Stryker accounts for about 3.0% of Tandem Capital Management Corp ADV’s investment portfolio, making the stock its 5th largest position. Tandem Capital Management Corp ADV’s holdings in Stryker were worth $5,886,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also modified their holdings of the company. Sachetta LLC lifted its position in shares of Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after buying an additional 27 shares during the period. Goodman Advisory Group LLC acquired a new stake in Stryker during the 1st quarter valued at $32,000. City Holding Co. increased its holdings in Stryker by 528.6% during the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock valued at $33,000 after purchasing an additional 74 shares in the last quarter. Ridgewood Investments LLC increased its holdings in Stryker by 48.4% during the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after purchasing an additional 30 shares in the last quarter. Finally, Ransom Advisory Ltd acquired a new stake in Stryker during the 1st quarter valued at $37,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 1.7%

NYSE:SYK opened at $375.35 on Thursday. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $143.50 billion, a P/E ratio of 49.72, a P/E/G ratio of 2.66 and a beta of 0.94. The stock’s fifty day simple moving average is $380.99 and its 200-day simple moving average is $378.83.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. During the same period last year, the company earned $2.81 EPS. The firm’s revenue was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities research analysts expect that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be issued a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a yield of 0.9%. Stryker’s payout ratio is currently 44.50%.

Analyst Ratings Changes

A number of research firms recently weighed in on SYK. Needham & Company LLC raised their price target on Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a report on Friday, August 1st. Redburn Partners set a $420.00 price target on Stryker in a report on Thursday, September 18th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Stryker in a report on Wednesday. Wells Fargo & Company lifted their target price on Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a research note on Friday, August 1st. Finally, BTIG Research reissued a “buy” rating on shares of Stryker in a research note on Monday, July 14th. Fifteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $430.10.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director directly owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.